Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. reported a net loss of $6.8 million for fiscal year 2025, an improvement from a net loss of $7.7 million in 2024. The company generated no revenue, with total operating expenses of $7.0 million, primarily driven by research and development ($3.0 million) and general and administrative costs ($3.9 million). Cash and cash equivalents stood at $5.2 million as of December 31, 2025, with total assets of $7.1 million and stockholders' equity of $6.0 million. The company used $6.1 million in operating cash flow but raised $7.1 million through financing activities, resulting in a net cash increase of $863,000. Management estimates cash resources will fund operations only through the third quarter of 2026 and requires at least $20 million in additional capital by fiscal year 2027 to continue development of its Symphony diagnostic platform.

Key Takeaways